Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia:...

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• Lovastatin, an HMG-CoA reductase inhibitor, is used to treat hyperlipidemia.
• Understanding lovastatin's precise effects on low-density lipoprotein (LDL) metabolism is crucial for optimizing cardiovascular disease management.
• Previous studies using tracers showed modest increases in LDL fractional catabolic rate (FCR) with HMG-CoA reductase inhibitor treatment.

Purpose of the Study:

• To differentiate the effects of lovastatin on LDL receptor activity versus LDL metabolic properties.
• To investigate the impact of lovastatin on LDL apolipoprotein B (apoB) turnover in hyperlipidemic subjects.
• To elucidate the mechanisms behind the observed modest increases in LDL FCR during statin therapy.

Main Methods:

• Eight hyperlipidemic subjects were studied during baseline and lovastatin treatment (40 mg/day).
• LDL tracers isolated during baseline (C-LDL) and treatment (Rx-LDL) were used to assess apoB turnover.
• In vivo studies in humans were corroborated by injecting LDL tracers into guinea pigs.

Main Results:

• Lovastatin significantly reduced total cholesterol, LDL cholesterol, and triglyceride levels.
• LDL receptor activity increased by 49%, while LDL apoB production rate decreased by 17%.
• A 15% decrease in LDL particle in vivo affinity for the LDL receptor was observed, partially offsetting increased receptor activity.

Conclusions:

• Lovastatin treatment enhances LDL receptor activity but also reduces LDL particle affinity for the receptor.
• The decrease in LDL particle affinity partially counteracts the beneficial effects of increased LDL receptors on LDL clearance.
• These findings explain the modest increases in LDL FCR previously observed with HMG-CoA reductase inhibitors.